MDGH is one of the world’s only not-for-profit biopharmaceutical companies, developing new medicines for people and communities who are disadvantaged by the traditional consideration of market returns.

 

MDGH’s expertise is in the product development process, which they apply to advancing medicines and vaccines that address important unmet medical needs, predominantly in low- and middle-income countries.

 

MDGH works with global colleagues, collaborators, and contributors at all stages of the process of investigating and implementing new and improved medicines for the treatment of neglected diseases. The company is currently developing moxidectin and CC-11050 for the treatment of 8 neglected tropical diseases.